GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety
Home › GLP-1 Hub
By Dr. Frank Yap, MD | Last updated: November 2026 | Purpose: evidence and safety education, not individual medical advice
Quick Answer
GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills: oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron), approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management. The 5 November 2026 Science special issue (“GLP-1 and Beyond”) examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyond classic metabolic disease—especially the brain—while highlighting the shift toward multi-receptor agents. Retatrutide is not approved anywhere; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regulated pharmacy.
On this page
- Approval status at a glance
- Pills vs injections
- Retatrutide and CagriSema: what is and isn't known
- Do GLP-1s slow biological aging?
- Safety, side effects and compounding risks
- Compounded, gray-market and research peptides: what are the risks?
- Evidence grades (CEBM)
- FAQ
- Disclosures & sources
1. Approval status at a glance
So far, GLP-1 agonist drugs—which repress hunger—have been approved for treating diabetes, chronic kidney disease, and obesity, and they can also be prescribed for some people who are overweight or at risk of certain cardiovascular diseases. And a lot of people are taking them. According to a 2026 Gallup poll, 11% of Americans are taking a GLP-1 drug for weight loss, up from 3% in 2024. And 15% of Americans say they’ve used one for weight loss at some point.
In the US, approved GLP-1-based medicines include semaglutide (Wegovy, Ozempic and the oral Wegovy pill), tirzepatide (Zepbound and Mounjaro) and orforglipron (Foundayo). Retatrutide and CagriSema remain investigational. Regulatory status changes quickly, so verify against the current FDA label before acting; this table is re-checked at each update.
| Medicine | Mechanism | Format | US status (Oct 2026) |
|---|---|---|---|
| Semaglutide (Wegovy / Ozempic) | GLP-1 | Weekly injection | Approved |
| Oral Wegovy (semaglutide 25 mg) | GLP-1 | Daily pill | Approved Dec 2025; EU approval July 15, 2026 |
| Tirzepatide (Mounjaro / Zepbound) | GIP + GLP-1 | Weekly injection | Approved |
| Orforglipron (Foundayo) | GLP-1 (non-peptide small molecule) | Daily pill | Approved April 1, 2026 (weight management) |
| CagriSema | GLP-1 + amylin | Injection | NDA filed December 18, 2025; decision expected Q4 2026 per Novo Nordisk; no public target date confirmed. Not approved. |
| Retatrutide | GIP + GLP-1 + glucagon | Weekly injection | Phase 3 (TRIUMPH) reported; Lilly plans a US submission in Q1 2027. Not approved anywhere. |
↔ Swipe the table sideways on mobile.
Regulatory status changes quickly. Verify against the current FDA label before acting; this table is reviewed at each update.
2. Are GLP-1 pills as effective as injections?
Your body naturally releases a hormone called GLP-1 (glucagon-like peptide-1) after eating. It signals your brain that you're full, slows digestion, and helps regulate blood sugar. The problem? Natural GLP-1 has a very short half-life of approximately 1–2 minutes because the enzyme DPP-4 rapidly breaks it down.
2026 is the year GLP-1 therapy moved beyond the needle. Foundayo has no food or water timing restrictions, which distinguishes it from oral semaglutide. Injectables, particularly the dual and triple agonists, currently show the largest average weight loss in trials, while pills offer convenience and different supply and cost considerations.
- Choose by priorities: maximum average weight loss, needle-free convenience, cost and coverage, tolerability history, and other conditions (heart, kidney, liver, sleep apnea).
- Do not compare trials naively. Populations, durations and doses differ; head-to-head data are limited.
- Medical supervision matters for dose escalation, side-effect management and long-term maintenance planning.
- Oral Wegovy vs Foundayo vs Weekly Injections: Which Is Best for Weight Loss in 2026?
- Ozempic Pill vs Wegovy Pill vs Foundayo: Comparison, Price and Side Effects (2026)
3. Retatrutide and CagriSema: what is known so far?
Retatrutide,
Eli Lilly's investigational GIP, GLP-1 and glucagon triple agonist, has produced the
largest weight loss reported in a Phase 3 obesity program, but it is not
approved and the results are sponsor-reported. CagriSema, Novo Nordisk's
amylin plus GLP-1 combination, is under FDA review.
What did the retatrutide Phase 3 trials report?
| Trial | Population | Result (highest dose unless stated) |
|---|---|---|
| TRIUMPH-1 (n = 2,339) | Obesity or overweight with a weight-related condition | 80 weeks: 17.6% (4 mg), 23.7% (9 mg), 25.0% (12 mg) vs 3.9% placebo. Subgroup with BMI of 35+ extended to 104 weeks: up to about 30%. Discontinuation for adverse events: 4.1%, 6.9%, 11.3% vs 4.9% placebo. |
| TRIUMPH-4 | Obesity with knee osteoarthritis | 28.7% at 68 weeks (12 mg), reported December 2025 |
| TRIUMPH-2 (n = 1,152) | Obesity or overweight with type 2 diabetes | 20.8% at 80 weeks (12 mg) vs 3.2% placebo per Lilly; HbA1c reduction up to 1.6% |
| TRIUMPH-3 (n = 1,949) | BMI of 35+ with established cardiovascular disease | Up to 22.6% at 80 weeks |
- Tolerability: in TRIUMPH-1 at the highest dose, nausea affected 42.4%, diarrhea 32.0%, constipation 26.1% and vomiting 25.3% of participants. Dysesthesia (abnormal skin sensation) and urinary tract infections were each reported in roughly one in ten participants on the highest doses.
- Timeline: Lilly said in July 2026 that it has the data package to support global submissions and plans a US submission in Q1 2027. Approval before 2027 is not expected.
- Knee Osteoarthritis: In TRIUMPH-4 and TRIUMPH-1-OA, published in the New England Journal of Medicine (9) in November 2026, found that retatrutide improved both body weight and knee osteoarthritis symptoms in people with obesity.
- Important: because retatrutide is not approved, any product sold as "retatrutide" outside a clinical trial is unapproved. Identity, quality and sterility cannot be assured. This hub does not provide dosing or sourcing guidance for unapproved compounds.
What is the status of CagriSema?
Novo Nordisk filed CagriSema with the FDA on December 18, 2025 and expects a decision in Q4 2026. In the REDEFINE 4 head-to-head trial (809 participants, 84 weeks), CagriSema produced 23.0% weight loss versus 25.5% for tirzepatide and did not meet its non-inferiority endpoint. It is not approved, and no approval date should be assumed.
4. Do GLP-1s slow biological aging?
Lilly and Novo Nordisk data suggest people on GLP-1s measured about two to three years “younger” on some biological-age markers. Clinicians caution against prescribing for anti-aging alone, and the research is early and not peer-reviewed.
Researchers at the University of California, Berkeley, reported in the journal Nature on Sept. 2 that female mice given the active ingredient in Novo Nordisk’s Ozempic and Wegovy had a median lifespan of 834 days, 12% higher than the 742 days recorded for untreated mice.
Novo Nordisk researchers reported separately that an analysis of 10,052 human patients across five early trials found that blood protein readings in GLP-1 users indicated their hearts were biologically two to four years younger than those of patients receiving a placebo. Similar biomarkers indicated that their kidneys, brains, pancreases and lungs were one to four years younger.
Eli Lilly reported in a separate analysis of overweight patients that 71 people older than 50 who took the active ingredient in their Mounjaro and Zepbound drugs for 72 weeks showed signs of their bodies aging 0.7 to 1.1 years. That was significantly lower than the 1.38 years the company expected.
Danica Chen, a UC Berkeley aging researcher who led the study published in Nature, said the 20-month-old female mice she analyzed were equivalent to 60-year-old human subjects.
Liz Skrbkova, who leads U.S. media and stakeholder relations for Novo Nordisk, said the Danish company “is exploring the new science of aging and is actively partnering to advance research in this field.”
She added, “It is not simply about adding more years to life, but to help people live healthier lives also as they grow older.”
She said semaglutide, the active ingredient in Wegovy and Ozempic, is “the only approved molecule with … evidence showing positive effects” on human aging across multiple body organs starting at 12 to 20 weeks of use.
“While this finding does not establish a cause-and-effect relationship, it provides valuable insights into semaglutide’s effects,” Ms. Skrbkova added.
A spokesperson for Indianapolis-based Eli Lilly shared a more guarded statement.
“This work is still early, and we’re continuing to build out these data,” the spokesperson said in an email. “We expect to have more to share down the road, and we’d be glad to stay in touch as that develops.”
Source: The Ozempic fountain of youth? Doctors wary of GLP-1 drugs’ anti-aging claims (The Washington Times - Oct 2026)5. Safety and side effects: what should patients know?
GLP-1 medicines are effective but not risk-free. Gastrointestinal side effects are common, and semaglutide and tirzepatide labels carry a boxed warning about thyroid C-cell tumors. Treatment should be supervised by a licensed clinician, with dose escalation and monitoring matched to the individual.
- Common side effects: nausea, vomiting, diarrhea and constipation, typically worst during dose escalation and often easing over time.
- Boxed warning: semaglutide and tirzepatide products carry a warning about thyroid C-cell tumors seen in rodents. They are not for people with a personal or family history of medullary thyroid carcinoma or MEN 2. Check each product's current label, including Wegovy pill and Foundayo.
- Other label-listed risks: pancreatitis, gallbladder disease, dehydration that can injure the kidneys, low blood sugar when combined with insulin or sulfonylureas, and allergic reactions.
- Pregnancy and contraception: GLP-1 medicines are not for use in pregnancy. Ask about contraception and pregnancy planning, because some labels advise changes to oral contraceptive use when starting tirzepatide.
- Lean mass and nutrition: weight loss includes some lean-mass loss. Protein intake, resistance training and nutrient monitoring matter; see How to Prevent Muscle Loss on GLP-1 Drugs and the GLP-1 Nutrient Deficiency Protocol.
- Surgery and anesthesia: tell your surgeon and anesthesia team that you use a GLP-1 medicine before any procedure.
Severe or persistent abdominal pain (especially if it spreads to the back), repeated vomiting, signs of dehydration such as very dark urine or dizziness, yellowing of the skin or eyes, or symptoms of a serious allergic reaction such as facial swelling or trouble breathing.
6. Compounded, gray-market and research peptides: what are the risks?
Compounded and gray-market GLP-1 products are not FDA-approved. The FDA states that compounded drugs are not reviewed for safety, effectiveness or quality before marketing, and that they are not the same as approved or generic medicines.
- Enforcement: on March 3, 2026, the FDA announced 30 warning letters to telehealth companies for false or misleading marketing of compounded GLP-1s, including implying equivalence with approved drugs and obscuring who compounds the product.
- How to reduce risk: ask whether the product is FDA-approved or compounded, who the prescriber is, and which state-licensed pharmacy dispenses it. For a structured checklist, read Telehealth Peptide Providers 2026.
- Research peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon): on July 23-24, 2026, the FDA Pharmacy Compounding Advisory Committee voted to recommend six of seven reviewed peptides for the 503A bulks list (BPC-157 by 8 to 6 with one abstention) and voted against emideltide (DSIP). The votes are non-binding, FDA staff flagged limited human evidence, and the FDA must still act. A vote is not approval.
See also: Peptide protocols guide and the peptide evidence review.
7. How strong is the evidence? (CEBM grades)
Key claims on this hub are labeled with Oxford CEBM levels: Level 1 = systematic review or high-quality randomized trial; 2 = lower-quality randomized trial or cohort; 3 = case-control; 4 = case series; 5 = expert opinion or mechanistic/preclinical. Regulatory facts are labeled "Regulatory record." Sponsor-reported topline results are flagged until peer-reviewed.
↔ Swipe the table sideways on mobile.
| Claim | Evidence base | Grade |
|---|---|---|
| Foundayo (orforglipron) FDA-approved April 1, 2026; about 12.4% weight loss at 72 weeks (ATTAIN-1, top dose) | FDA approval; Phase 3 RCT reported by Eli Lilly | Regulatory record / Level 1 (sponsor-reported) |
| Wegovy pill FDA-approved December 2025; about 13.6% weight loss at 64 weeks (OASIS 4) | FDA approval; Phase 3 RCT | Regulatory record / Level 1 |
| Tirzepatide 20.2% vs semaglutide 13.7% weight loss at 72 weeks (SURMOUNT-5) | Head-to-head randomized trial | Level 1 |
| Retatrutide 25.0% mean weight loss at 80 weeks, 12 mg (TRIUMPH-1) | Phase 3 RCT; sponsor topline and conference presentation | Level 1 design; confirm journal publication |
| Retatrutide up to about 30% at 104 weeks | Extension in a BMI 35+ subgroup that tolerated the dose | Exploratory; lower confidence |
| CagriSema 23.0% vs tirzepatide 25.5% (REDEFINE 4) | Head-to-head RCT; sponsor-reported | Level 1 (sponsor-reported) |
| Wegovy accelerated approval for MASH with F2-F3 fibrosis | ESSENCE trial and FDA decision | Level 1 / Regulatory record |
| BPC-157 and TB-500 benefits in humans | Mostly animal and preclinical data; FDA reviewers cite limited human evidence | Level 5 (mechanistic) |
| Safety of compounded and gray-market GLP-1 products | FDA statements and warning letters; reported adverse events | Regulatory record / Level 4 |
| Berberine and other supplements as GLP-1 substitutes | Mixed small trials on glucose and lipids; no equivalence to prescription GLP-1 therapy | Level 2-5, not a substitute |
8. Where to start: the complete GLP-1 evidence library
This hub is the entry point to the One Day MD GLP-1 library. Use the table to jump to the guide that matches your question, then follow the topic groups below.
| If you want to... | Read this guide |
|---|---|
| Understand the whole topic in one place | GLP-1 Manual 2026: The Complete Guide |
| Decide whether and how to start | Start GLP-1 Weight Loss 2026: Compare Options, Costs & Strategy; GLP-1 cost and coverage in US |
| Compare brand names (Ozempic, Wegovy, Mounjaro, Zepbound) | Ozempic vs Wegovy vs Mounjaro vs Zepbound |
| Protect muscle, bone and nutrition | Muscle loss prevention, bone density, nutrient monitoring |
| Know what happens when you stop | What Happens When You Stop GLP-1 |
| Choose a telehealth or peptide provider safely | Telehealth Peptide Providers 2026 |
Drug comparisons
- Semaglutide vs Tirzepatide vs Orforglipron: Which GLP-1 Drug Is Best in 2026?
- Tirzepatide vs Semaglutide: Zepbound vs Wegovy for Weight Loss, Diabetes & Heart Health
- Ozempic vs Wegovy vs Mounjaro vs Zepbound: Differences, Evidence, Safety and Access
- Ozempic vs Wegovy vs Mounjaro vs Trulicity
Muscle loss, bone density and nutrition
- Semaglutide vs Tirzepatide Muscle Loss: Which Preserves More Lean Mass?
- GLP-1 Muscle Loss: Protein, Resistance Training & Body Composition
- GLP-1 and Bone Density Loss
- GLP-1 Nutrient Deficiency Protocol 2026: Protein, Vitamins, Minerals & Lab Monitoring
Fatty liver
Knee Osteoarthritis
- GLP-1 for Knee Osteoarthritis: Pain Relief, Weight Loss, PRP, Stem Cells or Surgery?
Evidence, safety and the future
- GLP-1 Studies Explained: The Complete 2023-2026 Evidence Guide
- GLP-1 Side Effects and Safety
- GLP-1 2.0: The Next Generation of Obesity Drugs
- Peptide Academy: Complete Evidence-Based Guide
Suggested reading path (knowledge graph)
GLP-1 Hub → starting GLP-1 → muscle loss → bone density → nutrient monitoring → side-effect management → stopping GLP-1 → next-generation drugs → natural GLP-1 alternatives.
9. Frequently asked questions
What is a GLP-1 medicine?
A GLP-1 medicine mimics glucagon-like peptide-1, a gut hormone that raises insulin after meals, slows stomach emptying and reduces appetite. These prescription drugs treat type 2 diabetes and chronic weight management. Newer agents combine GLP-1 with other hormone targets, such as GIP (tirzepatide) or GIP plus glucagon (retatrutide, still investigational).
Which GLP-1 weight-loss pills are FDA-approved in 2026?
As of October 2026, two oral options are approved in the US for weight management: Wegovy pill (semaglutide 25 mg, approved December 2025) and Foundayo (orforglipron, approved April 1, 2026), the first non-peptide oral GLP-1. Foundayo has no food or water timing restrictions. Both need a prescription and clinical supervision.
Is retatrutide FDA-approved?
No. As of October 2026, retatrutide, a GIP, GLP-1 and glucagon triple agonist, is investigational and not approved anywhere. Eli Lilly reported positive Phase 3 TRIUMPH results and said in July 2026 it plans a US submission in the first quarter of 2027. Any retatrutide sold outside a clinical trial is unapproved and unverifiable.
How much weight did people lose with retatrutide in trials?
In the Phase 3 TRIUMPH-1 trial, average weight loss at 80 weeks was 17.6% (4 mg), 23.7% (9 mg) and 25.0% (12 mg), versus 3.9% with placebo, according to Lilly's topline report. A subgroup with BMI of 35 or higher reached up to about 30% at 104 weeks. These are sponsor-reported results that still need peer-reviewed confirmation.
Are GLP-1 pills as effective as injections?
On average, not quite. Wegovy pill produced about 13.6% weight loss at 64 weeks in OASIS 4 and Foundayo about 12.4% at 72 weeks at the top dose in ATTAIN-1. Injectable tirzepatide produced 20.2% versus 13.7% for semaglutide in the head-to-head SURMOUNT-5 trial. Trials differ, so do not compare numbers directly.
Is CagriSema FDA-approved?
Not yet. Novo Nordisk submitted CagriSema (cagrilintide plus semaglutide) to the FDA on December 18, 2025, and expects a decision in the fourth quarter of 2026, though no public target action date has been confirmed. In the REDEFINE 4 trial it produced 23.0% weight loss versus 25.5% for tirzepatide and missed its non-inferiority endpoint.
Are compounded or gray-market GLP-1 products safe?
They are not FDA-approved, and the FDA does not review compounded drugs for safety, effectiveness or quality before marketing. On March 3, 2026, the FDA sent 30 warning letters to telehealth companies over misleading compounded GLP-1 marketing. Quality, dose accuracy and sterility can vary, so use a licensed prescriber and a regulated, state-licensed pharmacy.
What are the most common GLP-1 side effects?
Nausea, vomiting, diarrhea and constipation are most common, typically worst during dose escalation. Semaglutide and tirzepatide labels also carry a boxed warning about thyroid C-cell tumors and list pancreatitis, gallbladder disease and dehydration risks. Discuss personal and family thyroid history with a physician before starting, and seek urgent care for severe abdominal pain.
Is BPC-157 legal or FDA-approved?
BPC-157 is not FDA-approved. In July 2026 an FDA advisory committee voted 8 to 6, with one abstention, to recommend adding it to the 503A bulks list, but the vote is non-binding and the FDA must still act. FDA reviewers noted limited human evidence. Do not treat the vote as approval or as a safety endorsement.
10. Supportive products and resources (affiliate links)
Nutrition and lifestyle products can support a prescribed treatment plan, but none is a GLP-1 medicine or a substitute for one. Supplements can interact with medicines, so review them with a pharmacist or physician. Affiliate links are marked below; see the disclosure.
| Item | What it is | Evidence note |
|---|---|---|
| Telehealth tirzepatide program (The Wellness Company) | A telehealth listing. Before ordering, confirm whether the product is FDA-approved or compounded, who prescribes it and which pharmacy dispenses it. | Compounded products are not FDA-approved (see section 5). |
| APPETITE (The Wellness Company) | Supplement marketed for appetite support; contains Akkermansia. | Not a GLP-1 drug. Human evidence for GLP-1-like effects is limited (Level 4-5). |
| PEAK METABOLISM (The Wellness Company) | Berberine and curcumin supplement for metabolic support. | Small trials show modest glucose and lipid effects (Level 2-5). May interact with medicines. |
| Bioavailable berberine (Amazon) | Berberine supplement. | Not equivalent to prescription GLP-1 therapy; ask a pharmacist about interactions. |
| Full Weight Management Collection (The Wellness Company) | Collection page. | Supportive products only. |
| Personalized virtual care (The Wellness Company) | Telehealth service for treatment personalization. | Use the provider checklist in Telehealth Peptide Providers 2026. |
11. Sources, disclosures and update log
Affiliate disclosure: Some links on One Day MD, including to The Wellness Company (referral code ONEDAYMD) and Amazon (as an Amazon Associate we earn from qualifying purchases), may earn us a commission at no extra cost to you. Affiliate relationships do not influence our evidence grading or safety statements, and no affiliate product is a substitute for prescribed GLP-1 therapy.
Medical disclaimer: This page is educational and does not constitute medical advice, diagnosis or treatment. Consult a licensed physician before starting, changing or stopping any medication. Never use unapproved or unverified products described as GLP-1 or peptide medicines.
Primary sources to verify
- FDA: FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s (March 3, 2026)
- Eli Lilly: FDA approves Foundayo (orforglipron) and retatrutide TRIUMPH-1 topline results (May 21, 2026)
- Novo Nordisk: European Commission approval of Wegovy pill and 7.2 mg pen (July 15, 2026)
- ClinicalTrials.gov: TRIUMPH-1 (NCT05929066)
- The Pharmaceutical Journal: Phase III retatrutide study demonstrates 30% weight loss
- AJMC: FDA approves oral semaglutide as first GLP-1 pill for weight loss
- Healio: FDA committee recommends looser restrictions for several peptides (July 24, 2026)
- Registers: Drugs@FDA labels (Wegovy, Zepbound, Foundayo) and European Commission and EMA announcements.
- See all sources and references.
- Join our newsletter for free on Substack.
Related
- Best GLP-1 Stocks (2026)
Update log
- October 16, 2026: Rebuilt hub. Corrected retatrutide TRIUMPH-1 figures (25.0% at 80 weeks at 12 mg; up to about 30% at 104 weeks in a subgroup) and the planned US submission timing (Q1 2027). Added CagriSema status, pill-vs-injection trial table, expanded evidence library and FAQ.
- October 2026: Initial publication of the GLP-1 Hub.
Explore this topic with AI
Ask our research assistant questions about this article, related clinical studies, medical evidence and other OneDayMD resources.
Explore with OneDayMD AIPowered by Google Gemini Notebook · Curated OneDayMD research sources
.png)
Comments